Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Novartis Licenses Incyte Therapies
by Rick Mullin
November 30, 2009
| A version of this story appeared in
Volume 87, Issue 48
Novartis has entered a licensing agreement giving it U.S. rights to drug discovery firm Incyte’s JAK inhibitor INCB18424, a treatment for the blood disease myelofibrosis in Phase III trials. It will also gain worldwide rights to Incyte’s early-stage cMET inhibitor INCB28060, a therapy targeting tumor invasion and drug resistance in certain cancers. Novartis will pay Incyte $150 million up front, an initial milestone payment of $60 million, and up to $1 billion in additional milestone payments
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter